Monday 27 February 2017

Therapeutic Tolerance - First in Human Data DRAFT PROGRAMME

THERAPEUTIC TOLERANCE: FIRST-IN-HUMAN DATA
 
 
27th - 30th June 2017
Research Beehive, Old Library Building,
Newcastle University, Newcastle upon Tyne
 
DRAFT PROGRAMME
 
Tuesday 27th June
 
12.00
Registration and lunch
 
 
 
13.30
Professor John Isaacs
Welcome and introduction
 
13.40
 
Keynote speaker
Ron Germain (NIH, USA)
 
 
Imaging the immune system
 
Session 1- Cells and Mechanisms
Chaired by John Isaacs
14.30
Georg Hollander (Oxford, UK)
The Thymus – a 2017 perspective
14.50
Ethan Shevach (NIH, USA)
What’s the latest in regulatory T-cells
15.10
Herman Waldmann (Oxford, UK)
Novel antibodies with improved properties
15.30
David Samson (UCL, UK)
What does CTLA4 really do?
15.50
Discussion
 
16.10
Coffee break (Poster/exhibitor viewing)
 
 
 
 
Session 2 – Breaking Tolerance in Cancer
Chaired by Andy Mellor
16.30
Samir Khleif (Augusta, USA)
Rational design for combination immunotherapy
16.50
Ted Johnson (Augusta, USA)
Trials and tribulations in breaking tumour tolerance
17.10
Dario Vignali (Pittsburgh, USA)
Tolerance and cancer
17.30
Robert Wilkinson (Medimmune)
Immunological targets to combat cancer
17.50
Discussion
 
 
 
 
19.00 (TBC)
Conference dinner
 
Wednesday 28th June
 
Session 3 – New Concepts in Tolerance
Chaired by
08.30
Tea/coffee
 
08.45
 
 
09.05
Paul-Peter Tak (Stevenage, UK)
Immunomodulation by vagal nerve stimulation
09.25
George Kassiotis (CRICK, UK)
Endogenous retroviruses and the breakdown of immune tolerance
09.45
Femke van Wijk (Utrecht, Netherlands)
Resetting T-cell regulation in Juvenile Idiopathic Arthritis
10.05
Ignacio Anegnon (Nantes, France)
Novel mechanisms in tolerance induction
10.25
Discussion
 
10.45
Coffee break (Poster/exhibitor viewing)
 
Session 4 – Short oral presentations
Chaired by
11.05
 
 
11.20
 
 
11.35
 
 
11.50
 
 
12.05
 
 
12.20
Lunch (Poster/exhibitor viewing)
 
Session 5 – Tolerance Biomarkers in Autoimmune Disease
Chaired by
13.20
Maria Hernandez-Fuentes (KCL, UK)
Biomarkers in transplantation tolerance
13.40
John Isaacs (Newcastle, UK)
Update on the RA-MAP consortium
14.00
Georg Schett (Erlangen, Germany)
Autoantibodies as tolerance biomarkers
14.20
Helmut Jonuleit (Mainz, Germany)
Tolerogenic targets in regulatory T-cells
14.40
Anish Suri (Turnhoutseweg, Belgium)
Parsing the TCR repertoire in RA to enable tolerogenic trials
15.00
Discussion
 
15.20
Coffee break (poster/exhibitor viewing)
 
 
 
 
 
The Great Debate (1)
Chaired by
 
15.40
Debate: Therapeutic Tolerance: Pie-in-the-Sky or Just-Around-the-Corner?
16.40
Poster session
18.40
Close
 
 
 
Thursday 29th June
 
Session 6 – Cellular Therapies – first-in-human results
Chaired by
 
08.30
Tea/coffee
 
08.45
Giovanna Lombardi (KCL, UK)
Tregs in kidney transplantation – first-in-human data
09.05
Piotr Trzonkowski (Gdansk, Poland)
Tregs therapies in type I diabetes
09.25
Maria Ester Bernardo (Milan, Italy)
Mesenchymal stem cells for tolerance induction in human disease
09.45
Catharien Hilkens (Newcastle, UK)
AuToDeCRA
10.05
 
 
10.25
Discussion
 
10.45
Coffee break (Poster/exhibitor viewing)
 
Session 7 - Peptides
Chaired by
11.05
David Wraith (Birmingham, UK)
Apitope therapy in MS and other conditions
11.25
Mark Peakman (KCL, UK)
Peptide therapy in diabetes
11.45
Kei Kishimoto (Massachusetts, USA)
Tolerogenic nanoparticles
12.05
Ranjeny Thomas (Brisbane, Australia)
A platform for peptide therapeutics
12.25
Willem van Eden (Utrecht, the Netherlands)
The enigma of heat shock proteins in immune tolerance
12.45
Discussion
 
13.05
Lunch (Poster/exhibitor viewing)
 
Session 8 – Tolerogenic Antibody Therapy
Chaired by
14.05
Lucienne Chatenoud (Paris, France)
Anti-CD3 – an update
 
14.25
Alasdair Coles (Cambridge, UK)
Alemtuzumab in Multiple Sclerosis
 
14.45
Andy Cope (KCL, UK)
Treating very early autoimmunity
 
15.05
Mike Ehrenstein (UCL, UK)
Anti-TNF as a tolerogenic therapy
 
15.25
 
 
 
15.45
 
 
 
16.05
Discussion
 
 
16.25
Coffee break (Poster/exhibitor viewing)
 
 
 
The Great Debate (2)
Chaired by
 
16.45
Debate:
17.45
Close
 
 
19.00 (ish)
Conference dinner
 
Friday 30th June
 
08.30
Tea/coffee
 
08.45
Keynote speaker
Lars Klareskog (Stockholm, Sweden)
 
Evolution of an autoimmune disease – a window of opportunity for tolerance induction?
 
Session 9 – Metabolism and Metabolomics
Chaired by
 
09.35
Andy Mellor (Newcastle, UK)
IDO and tolerance – where are we now?
09.55
Hozefa Bandukwala (Massachusetts, USA)
Anti-anabolic drugs and immunosuppression
10.15
Duncan Howie (Oxford, UK)
How FoxP3 regulates immune metabolism
10.35
 
 
10.55
Discussion
 
11.15
Coffee break (Poster/exhibitor viewing)
 
Session 10 – Immunotherapeutics
Chaired by
11.35
Jaap van Laar (Utrecht, Netherlands)
Hematologic transplantation as a therapy for autoimmunity
11.55
Andreas Radbruch (Berlin, Germany)
Restoring B cell tolerance
12.15
Michelle Rosenzwajg (Paris, France)
Low dose IL-2 therapy
12.35
Luis Graca (Lisbon, Portugal)
Tolerance to Factor VIII
12.55
Claudia Mauri (London, UK)
Regulatory B Cells
13.05
Discussion
 
13.25
Closing remarks and poster prizes (lunch)
 
 
 
 

Sophie Hambleton PI Seminar - TODAY

Should be good!

 

 

 

PI Seminar Series

 

Speaker:         Professor Sophie Hambleton

Venue:            Baddiley Clark Seminar Room

Date:               Monday 27th February 2017

Time:               13.00-14.00

 

 

Professor Sophie Hambleton will present:

 

'The troubled immune system - molecular origins of early onset immune dysregulation"

 

Abstract

The molecular dissection of monogenic primary immunodeficiency disorders (PIDs) offers a powerful means to discover genes and pathways that are important for human immunity. PIDs are inborn errors of the immune system that typically present in young children with susceptibility to infection, but may also manifest as early onset immune dysregulation (autoimmunity, autoinflammation, lymphoproliferation). The elucidation of causal alleles in such patients can produce paradigm shifts in understanding, as exemplified by the link between FOXP3 mutation, a devastating syndrome of autoimmune enteropathy and endocrinopathy in male infants, and the lack of regulatory T cells. By linking genotype to phenotype in a human host in the natural environment, such research provides a critical adjunct to animal models.  Furthermore, Mendelian disorders can help to elucidate the molecular mechanism of putative causal variants discovered through genome-wide association studies in common diseases.

 

The identification of novel disease genes is of demonstrable benefit to patient care, opening up the important possibilities of early diagnosis, pre-emptive therapy and genetic counseling. It can lead to improved understanding of the natural history of individual disorders, and an obvious opportunity for "precision medicine". Yet in paediatric immunology practice, we see a constant stream of children with severe PID phenotypes that currently lack a molecular explanation. In this talk I will show how my research group addresses this significant unmet clinical need, and harnesses the potential these disorders represent for scientific discovery.

 

 

Chair: Professor Andy Mellor